Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 18:12:35·⟳ 抓取 18:13:04 +29s·⚡ 决策 10-19 18:24:18 +11m14s·8.2 天前
IDEAYA将于ESMO 2026公布darovasertib葡萄膜黑色素瘤三项研究数据，但核心数据此前已披露
这是会议开幕前4天的AI生成预告稿：核心注册性OptimUM-02顶线数据2026年4月13日已公布、完整数据已于2026 ASCO以late-breaking口头报告展示，ESMO展示安排7月17日已公告，NDA 2026下半年递交为既有指引；本稿未提供任何新数据点或新里程碑，标题还混入无关的油价文字，属低质量聚合，无事件驱动edge。
📄 原文Investing.com↗ 原文
IDEAYA presents uveal melanoma trial data at ESMO 2026
Oil prices dip as Trump waives Russia sanctions SOUTH SAN FRANCISCO, Calif. - IDEAYA Biosciences Inc. (NASDAQ:IDYA) ann…
不做 IDEAYA Biosciences（IDYA.US）
无新增事实：OptimUM-02顶线4月已发、完整数据ASCO已公布、ESMO日程7月已公告、NDA时间表为既有指引；该Investing.com稿为AI生成的会前预告，当前美股盘前也无成交窗口，不构成可交易edge。可待10月23-27日ESMO现场出现真正更新数据或NDA正式递交时再评估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
IDEAYA的darovasertib ESMO数据均为ASCO及财报已披露内容的再展示，NDA时间表未变，本条新闻无增量信息；IDYA近20日累计下跌约14.5%且处于下行通道，不宜据此抢跑做多，等待10月23日大会现场是否有超预期更新。
消息传播链
- AI生成、经编辑审核的ESMO会前数据预告，非公司一手新闻稿，且标题混入无关油价文字，信息全部来自既有披露
关键理由
- 数据本身积极（OptimUM-02 mPFS 6.9 vs 3.1个月），支撑NDA逻辑，但均已在4-6月公开并被市场消化
主要风险
- ESMO现场若公布更长期OS更新或新增安全性问题可能引发双向跳空，当前时点提前下注无信息优势
- 公司无营收、PE为负，股价近一个月持续走弱，事件前弱势环境下利好预告易被卖出
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-19 · 影响 weakens
未发现本稿之外的新增数据或NDA提前/推迟信息；IDYA近5日-9%、近20日-14.5%，处于持续下行趋势，无资金抢跑迹象也无右侧确认
检索:IDEAYA darovasertib ESMO new data NDA delay setback 原文 ↗
先例如何影响了这次决策
对本次决策的影响:不影响AVOID结论；真正值得评估的催化是10月23-27日ESMO现场数据及NDA正式递交
涨幅量级:未做先例定价：结论基于无新增事实的早停式判断，不需要先例校准幅度
工具执行结果 · 成功 5 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`ideaya darovasertib uveal melanoma esmo 2026 optimum data | idya darovasertib crizotinib nda first-line metastatic uveal melanoma | optimum-01 optimum-02 pfs overall survival darov`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - web_search 成功 doubao_search · 1,410 ms
豆包搜索结果（原始查询:IDEAYA Biosciences GSK acquisition close darovasertib IDYA delisted；API SearchType:web） - web_search 成功 doubao_search · 1,286 ms
豆包搜索结果（原始查询:IDEAYA darovasertib ESMO 2026 OptimUM-02 NDA uveal melanoma press release；API SearchType:web） - web_search 成功 doubao_search · 1,347 ms
豆包搜索结果（原始查询:IDEAYA announces ESMO 2026 darovasertib data October press release uveal melanoma；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 196 ms
{
原文全文
展开原文 · 2,044 字
Oil prices dip as Trump waives Russia sanctions
SOUTH SAN FRANCISCO, Calif. - IDEAYA Biosciences Inc. (NASDAQ:IDYA) announced clinical trial data from three studies evaluating darovasertib in uveal melanoma patients to be presented at the European Society for Medical Oncology Congress 2026, taking place October 23-27 in Madrid, according to a press release statement.
The OptimUM-01 Phase 2 study evaluated darovasertib combined with crizotinib in 101 HLA-A02:01-positive metastatic uveal melanoma patients with median follow-up of 10.4 months. Treatment-naïve patients showed a median progression-free survival of 7.4 months and median overall survival of 27.1 months. The overall response rate was 36.4% in treatment-naïve patients and 35.7% in patients who received prior tebentafusp treatment. The most common treatment-related adverse events included diarrhea, nausea, peripheral edema and vomiting, with 8.9% of participants discontinuing treatment due to related adverse events.
The OptimUM-02 Phase 2/3 trial in first-line HLA-A02:01-negative metastatic uveal melanoma showed median progression-free survival of 6.9 months for darovasertib plus crizotinib versus 3.1 months for investigator’s choice of therapy. Subgroup analyses demonstrated consistent improvements in response rates and progression-free survival across multiple patient subgroups.
The OptimUM-09 Phase 2 trial evaluated single-agent darovasertib before local treatment in 116 primary uveal melanoma patients. Tumor shrinkage of at least 20% occurred in 57.8% of patients. The study showed a 57% eye preservation rate in the enucleation cohort and 66% of patients in the plaque brachytherapy cohort had reduced planned radiation dose to critical eye structures.
IDEAYA is submitting a new drug application for darovasertib combined with crizotinib for first-line metastatic uveal melanoma and expects to complete the submission in the second half of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SOUTH SAN FRANCISCO, Calif. - IDEAYA Biosciences Inc. (NASDAQ:IDYA) announced clinical trial data from three studies evaluating darovasertib in uveal melanoma patients to be presented at the European Society for Medical Oncology Congress 2026, taking place October 23-27 in Madrid, according to a press release statement.
The OptimUM-01 Phase 2 study evaluated darovasertib combined with crizotinib in 101 HLA-A02:01-positive metastatic uveal melanoma patients with median follow-up of 10.4 months. Treatment-naïve patients showed a median progression-free survival of 7.4 months and median overall survival of 27.1 months. The overall response rate was 36.4% in treatment-naïve patients and 35.7% in patients who received prior tebentafusp treatment. The most common treatment-related adverse events included diarrhea, nausea, peripheral edema and vomiting, with 8.9% of participants discontinuing treatment due to related adverse events.
The OptimUM-02 Phase 2/3 trial in first-line HLA-A02:01-negative metastatic uveal melanoma showed median progression-free survival of 6.9 months for darovasertib plus crizotinib versus 3.1 months for investigator’s choice of therapy. Subgroup analyses demonstrated consistent improvements in response rates and progression-free survival across multiple patient subgroups.
The OptimUM-09 Phase 2 trial evaluated single-agent darovasertib before local treatment in 116 primary uveal melanoma patients. Tumor shrinkage of at least 20% occurred in 57.8% of patients. The study showed a 57% eye preservation rate in the enucleation cohort and 66% of patients in the plaque brachytherapy cohort had reduced planned radiation dose to critical eye structures.
IDEAYA is submitting a new drug application for darovasertib combined with crizotinib for first-line metastatic uveal melanoma and expects to complete the submission in the second half of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
aef11e9988· 2026-10-19 18:24 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前